The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.
Boccon-GibodL., LeleuC., HerveJ.M., BelasM., StegA.: Bladder tumours invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression. In: DebruyneFMJ, denisL, van der MeijdenAPM (Eds): BCG in superficial bladder cancer.Alan R Liss, New-York1989, pp. 161–170.
2.
VicenteJ., LagunaF., DuarteD., ChechileG.: Oncological identity of G3 pT1 bladder cancer. IXth Congress of the European Association of Urology, Amsterdam, June 13–16, 1990. Eur. J. Urol. (Suppl. 1): 69(abstr. 132); 1990.
3.
CuderS.J., HeneyN.M., FriedeilG.H.: Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: BonneyW.W., ProutG.R.: Bladder Cancer.Williams & Wilkins, Baltimore, 1982, pp. 35–46.
4.
HeneyN.M., AhmedS., FlanaganM.J.: Superficial bladder cancer: progression and recurrence. J. Urol., 130: 1083–86, 1983.
5.
PauwelsR.P.E., SchapersR.F.M., SmeetsA.W.G.: Grading in superficial bladder cancer. Morphological criteria. Brit. J. Urol., 61: 129–134, 1988.
6.
LammD.L., GriffithJ.G.: Intravesical therapy: does it affect the natural history of superficial bladder cancer?Seminars in Urology, 10: 39–44, 1992.
7.
HerrH.W.: Progression of stage Tl bladder tumours after intravesical bacillus Calmette-Guerin. J. Urol., 145: 40–44, 1991.
8.
Dal BoV., BelmonteP., VeronesiA., Lo ReG., MiottoE., MerloA., VolpeR., FranciniM.: Intravesical BCG instillations in patients with carcinoma in situ and pT1 G3 transitional cell carcinoma of the bladder. Eur. Urol., 18 (Suppl. 1): 43 (Abstr. 82), 1990.
9.
MorelliB., RandoneD.F., TerroneC., Rocca RossettiS.: Quai è il miglior trattamento per il carcinoma vescicale di epitelio transizionale G3 T1. Acta Urol. Ital., (Suppl. 4): 155–56, 1992.
10.
EureG.R., CundiffM.R., SchellhammerP.F.: Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J. Urol., 147: 376–79, 1992.
11.
BouffiouxC.H., DenisL., OosterlinckW., ViggianoG., VergisonB., KeuppensF., de PauwM., SylvesterR., CheuvartB.and members of the European Organization for Research on Treatment of Cancer Genitourinary Group: Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research and Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J. Urol., 148: 297–301, 1992.
